From the Department of Orthopeadic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA (Dr. Bolia, and Dr. Tan), and the Danville Orthopeadics and Sports Medicine, Danville, KY (Dr. Covell).
J Am Acad Orthop Surg Glob Res Rev. 2024 May 2;8(5). doi: 10.5435/JAAOSGlobal-D-23-00216. eCollection 2024 May 1.
Graft materials available to supplement hindfoot and ankle arthrodesis procedures include autologous (autograft) or allogeneic bone graft (allograft) but also bone graft substitutes such as demineralized bone matrix, calcium sulfate, calcium phosphate, and tricalcium phosphate/hydroxyapatite. In addition, biologic agents, such as recombinant human bone morphogenetic protein-2 or recombinant human platelet derived growth factor-BB (rhPDGF-BB), and preparations, including platelet-rich plasma or concentrated bone marrow aspirate, have been used to facilitate bone healing in ankle or hindfoot arthrodesis. The purpose of this review was to summarize the available clinical evidence surrounding the utilization and efficacy of the above materials and biological agents in ankle or hindfoot arthrodesis procedures, with emphasis on the quality of the existing evidence to facilitate clinical decision making.
用于补充后足和踝关节融合术的移植物材料包括自体(自体移植物)或同种异体骨移植物(同种异体移植物),但也包括骨移植物替代品,如脱钙骨基质、硫酸钙、磷酸钙和磷酸三钙/羟基磷灰石。此外,生物制剂,如重组人骨形态发生蛋白-2 或重组人血小板衍生生长因子-BB(rhPDGF-BB)以及制剂,包括富含血小板的血浆或浓缩骨髓抽吸物,已被用于促进踝关节或后足融合术的骨愈合。本综述的目的是总结围绕上述材料和生物制剂在踝关节或后足融合术中的应用和疗效的现有临床证据,重点是现有证据的质量,以促进临床决策。